Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer entities : Beigene, ltd. save search
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Published: 2024-04-08 (Crawled : 10:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 0.0%
H: 1.76%
C: -0.62%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.94%
H: 1.12%
C: 0.61%
association cancer research preclinical for meeting
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - globenewswire.com
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.0%
H: 3.14%
C: 1.07%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.54%
H: 0.46%
C: -1.09%
association cancer research preclinical meeting
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-02-26 (Crawled : 11:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.6%
H: 1.87%
C: 0.7%
lung chmp positive cancer cell treatment
FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer
Published: 2023-12-13 (Crawled : 21:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.91%
H: 2.03%
C: 1.4%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.11%
H: 0.5%
C: -1.78%
fda lung review cancer cell application grants advanced
Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
Published: 2023-12-08 (Crawled : 21:00) - biospace.com/
JAZZ | $109.96 0.63% 0.63% 760K
|
Health Technology
|
| O: 0.83%
H: 1.11%
C: -0.1%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.32%
H: 0.78%
C: -1.13%
breast cancer pharmaceuticals sabcs potential
AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) PLUS VECTIBIX® (PANITUMUMAB) DATA IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2023-10-22 (Crawled : 16:20) - prnewswire.com
CCXI | $51.99 -0.04%
|
Health Technology
| Email alert
Add to watchlist
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
| Email alert
Add to watchlist
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
| Email alert
Add to watchlist
BEIGF | $14.29 -9.87% 2.1K
|
n/a
| Email alert
Add to watchlist
lumakras cancer plus
AMGEN PRESENTS NEW TARLATAMAB DATA IN SMALL CELL LUNG CANCER
Published: 2023-10-20 (Crawled : 12:00) - prnewswire.com
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.33%
H: 5.87%
C: 5.53%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 0.0%
H: 0.16%
C: -0.64%
lung cancer cell
BeiGene Announces the Phase 3 RATIONALE 315 Trial Met Primary Endpoints of Major Pathological Response Rate and Event-Free Survival for Tislelizumab Plus Chemotherapy in Patients with Resectable Non-Small Cell Lung Cancer (NSCLC)
Published: 2023-10-17 (Crawled : 21:00) - biospace.com/
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -2.74%
H: 2.94%
C: 1.41%
lung cancer cell trial response plus
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245, a Selective Next-Generation B-RAF Inhibitor, in Adult Patients with Advanced or Refractory Solid Tumors at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-17 (Crawled : 19:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: 1.32%
H: 3.79%
C: -0.12%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.83%
H: 1.34%
C: -0.08%
bgb-3245 association tumors cancer research meeting
SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023
Published: 2023-04-17 (Crawled : 19:00) - globenewswire.com
SWTX | $40.075 -5.64% -5.98% 1.4M
|
Health Technology
|
| O: 1.32%
H: 3.79%
C: -0.12%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.83%
H: 1.34%
C: -0.08%
association tumors cancer research meeting
Zymeworks to Present Updated Data on Multiple Product Candidates at the American Association for Cancer Research (AACR) Annual Meeting
Published: 2023-03-14 (Crawled : 23:00) - biospace.com/
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 1.45%
H: 4.42%
C: 1.19%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 6.65%
H: 0.83%
C: -2.4%
research meeting association cancer
New Clinical Data for Zanidatamab in HER2+ /HR+ Metastatic Breast Cancer Presented Today at 2022 SABCS
Published: 2022-12-09 (Crawled : 17:00) - biospace.com/
ZYME | $8.85 2.08% 2.03% 550K
|
Health Technology
|
| O: 2.26%
H: 13.54%
C: -7.32%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 1.65%
H: 1.85%
C: -3.47%
sabcs breast cancer her2+ today her2- her2 metastatic breast cancer
HUTCHMED Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China
Published: 2022-11-14 (Crawled : 00:00) - hutch-med.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.92%
H: 0.48%
C: -0.84%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.05%
H: 1.74%
C: -0.5%
topline china positive cancer study
Leap Therapeutics Announces First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients
Published: 2022-10-17 (Crawled : 12:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: -1.14%
H: 4.6%
C: 3.24%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 4.91%
H: 6.28%
C: 2.04%
dkn-01 treatment therapeutics leap cancer study
Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 DisTinGuish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer
Published: 2022-10-12 (Crawled : 14:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: 0.7%
H: 2.79%
C: 0.24%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 2.77%
H: 20.74%
C: 17.3%
dkn-01 treatment therapeutics leap cancer study
Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting
Published: 2022-10-05 (Crawled : 17:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: 0.22%
H: 0.39%
C: -2.49%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -0.17%
H: 0.08%
C: -0.29%
dkn-01 preclinical meeting therapeutics plus leap cancer study
LUMAKRAS® (SOTORASIB) COMBINED WITH VECTIBIX® (PANITUMUMAB) SHOWS CONFIRMED 30% OBJECTIVE RESPONSE RATE IN PATIENTS WITH KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER
Published: 2022-09-12 (Crawled : 09:00) - prnewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras response cancer
LUMAKRAS®/LUMYKRAS® (SOTORASIB) DEMONSTRATES SUPERIOR PROGRESSION-FREE SURVIVAL OVER DOCETAXEL IN FIRST POSITIVE PHASE 3 TRIAL OF A KRAS G12C INHIBITOR IN NON-SMALL CELL LUNG CANCER
Published: 2022-09-11 (Crawled : 00:00) - prnewswire.com
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: 0.6%
H: 1.16%
C: 0.17%
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: -0.16%
H: 0.16%
C: 0.06%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: -1.88%
H: 3.78%
C: 3.73%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -3.91%
H: 1.55%
C: -0.16%
lumakras lung trial positive cancer
AMGEN ANNOUNCES TOPLINE DATA FROM LUMAKRAS® (SOTORASIB) PHASE 3 TRIAL IN NON-SMALL CELL LUNG CANCER
Published: 2022-08-30 (Crawled : 21:00) - prnewswire.com
CCXI | $51.99 -0.04%
|
Health Technology
|
| O: 0.12%
H: 0.16%
C: -0.31%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 3.3%
H: 1.98%
C: 0.39%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: 1.03%
H: 0.95%
C: -0.53%
lumakras lung topline trial cancer
Leap Therapeutics' Board of Directors Member Dr. Monica Bertagnolli Appointed as the Director of the National Cancer Institute
Published: 2022-08-12 (Crawled : 12:00) - biospace.com/
LPTX | $2.81 -5.07% -5.34% 200K
|
Health Technology
|
| O: 1.54%
H: 6.82%
C: -2.27%
BGNE | $129.51 -1.86% -1.89% 300K
|
Health Technology
|
| O: 0.67%
H: 0.83%
C: -2.01%
leap cancer
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.